News
Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumorsNew candidate APVO455 targets Nectin-4+ cancers, joins miple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback